Safety, Side Effects, and Clinical Considerations Before Starting Semaglutide Safety remains a central consideration in any medically guided weight loss program
others raise concerns that the drugs worsen symptoms
At 36 weeks, retatrutide led to a maximum HbA1c reduction of 2.2%, while dulaglutide reduced it by 1.4%, and the placebo group by 0.3%
A: GLP-1 Agonists, including Semaglutide and Tirzepatide for weight loss, work by slowing down gastric emptying, increasing feelings of fullness, and reducing hunger
GLP-1 therapies act comprehensively on this metabolic substrate, simultaneously addressing insulin resistance, hepatic inflammation, adipokine dysregulation, and systemic oxidative stress